Pharmacological validation of the chronic mild stress model of depression

European Journal of Pharmacology

Volumn 296, Issue 2, 1996, Pages 129-136

  Papp, Mariusz ^a   Moryl, Elisabeta ^a   Willner, Paul ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Depression, animal model; Pharmacological validation; Stress, Chronic, mild

Indexed keywords

ANTIDEPRESSANT AGENT; ATROPINE; BROFAROMINE; BUSPIRONE; CHLORPROTHIXENE; DEXAMPHETAMINE; HALOPERIDOL; IMIPRAMINE; MEPYRAMINE; MORPHINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SUCROSE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRINKING; FLUID INTAKE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STRESS;

EID: 0030033891     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00697-4     Document Type: Article

References (58)

1. Antkiewicz-Michaluk, L., 1986, The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system, Pol. J. Pharmacol. Pharm. 38, 359.
2. Ayd, F.J., Jr. and J. Zohar, 1987, Psychostimulant, amphetamine and methylphenidate, therapy for chronic and treatment-resistant depression, in: Treating Resistant Depression, ed. J. Zohar and R.H. Belmaker (PMA Corp., New York) p.343.
3. Beckman, H. and H.-W. Moise, 1982, The cholinolytic biperiden in depression: An acute placebo-controlled study, Arch. Psychiatr. Nervenkr. 231, 213.
4. Beckman, H. and M. Schmauss, 1983, Clinical investigations into antidepressive mechanisms. I. Antihistaminic and cholinolytic effects: amitriptyline versus promethazine, Arch. Psychiatr. Nervenkr. 233, 59.
5. Borowski, T.S. and L. Kokkinidis, 1992, Long-term influence of d-amphetamine on mesolimbic brain-stimulation reward: comparison to chronic haloperidol and naloxone effects, Pharmacol. Biochem. Behav. 43, 1.
6. Carlsson, A. and M. Lindqvist, 1969, Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines, J. Pharm. Pharmacol. 21, 460.
7. Cheeta, S., C. Broekkamp and P. Willner, 1994, Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer, Psychopharmacology 116, 523.
8. Chouinard, G., B.M. Saxena, N.P.V. Nair, S.P. Kutcher, D. Bakish, J. Bradwein, S.H. Kennedy, V. Sharma, R.A. Remick, S.A. KukhaMohamad, L. Beauclair, J. Snaith and J.D. Souza, 1993, Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies, Clin. Neuropharmacol. 16, Suppl. 2, S51.
9. Delina-Stula, A., E. Radeke and H. Van Riezen, 1988, Enhanced functional responsiveness of the dopaminergic system: the mechanism of anti-immobility effects of antidepressants in the behavioural despair test in the rat, Neuropharmacology 27, 943.
10. Del Zompo, M., A. Bocchetta, F. Bernardi, C. Burrai and G.U. Corsini, 1990, Clinical evidence for a role of dopaminergic systeme in depressive syndromes, in: Dopamine and Mental Depression, ed.G.L. Gessa and G. Serra (Pergamon, Oxford) p. 177.
11. Denber, H.C., P. Rajotte and E. Ross, 1960, Some observations on the chemotherapy of depression; results with 'Taractan', Compr. Psychiatr. 1, 308.
12. Emrich, H.E.M., 1987, Opioids as a possible treatment for resistant depression, in: Treating Resistant Depression, ed. J. Zohar and R.H. Belmaker (PMA Corp., New York) p. 381.
13. Extein, I., D. Pickar, M.S. Gold, P.W. Gold, A.L.C. Pottash, D.R. Sweeney, R.J. Ross, R. Rebard, D. Martin and F.K. Goodwin, 1981, Methadone and morphine in depression, Psychopharmacol. Bull. 17, 29.
14. Fabre, L.F., 1990, Buspirone in the management of major depression: A plcaebo-controlled comparison, J. Clin. Psychiatr. 51, Suppl., 55.
15. Fritze, J., 1993, The adrenergic-cholinergic imbalance hypothesis of depression: A review and a perspective, Rev. Neurosci. 4, 63.
16. Gelenberg, A.J., 1994, Buspirone: Seven-year update, J. Clin. Psychiatr. 55, 222.
17. Gerner, R.H., D.H. Catlin, D.A. Gorelick, K. Hui and C.H. Li, 1980, Beta endorphin: intravenous infusion causes behavioral change, Arch. Gen. Psychiatr. 37, 642.
18. Giannini, A.J., L.O. Gregg and J.P. Andriano, 1984, P's and blues: potentiation of propoxyphene withdrawal by a variety of antihistamines, J. Clin. Toxicol. 22, 397.
19. Gillin, J.C., L. Sutton, C. Ruiz, D. Darko, S. Golshan, S.C. Risch and D. Janowsky, 1991, The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group, Biol. Psychiatr. 30, 157.
20. Hall, H. and S.-O. Ögren, 1984, Effects of antidepressant drugs on histamine-H1 receptors in the brain, Life Sci. 34, 597.
21. Hankoff, L.D., R.H. Grundlach, H.M. Paley and L. Rudorfer, 1964, Diphenhydramine as an antidepressant, Dis. Nerv. Syst. 25, 547.
22. Hoch, P.H. and W. Mauss, 1932, Atropin Behandlung bei Geisteckrankheiten, Arch. Psychiatr. Nervenkr. 97, 546.
23. Janowsky, D.S. and D.H. Overstreet, 1990, Cholinergic dysfunction in depression, Pharmacol. Toxicol. 66, Suppl., 100.
24. Janowsky, D.S. and S.C. Risch, 1984, Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress, Drug. Dev. Res. 4, 125.
25. Katz, R.J. and M. Sibel, 1982, Further analysis of the specificity of a novel animal model of depression: effects of an antihistaminic, antipsychotic and anxiolytic compound, Pharmacol. Biochem. Behav. 16, 979.
26. Kielholz, P., 1963, Pharmakologische Therapie der Depresssionen in der Praxis, Monatskurze Arztl. Fortbild. 13, 549.
27. Kraepelin, E., 1901, Einführung in die Psychiatrishe Klinik (Joh Ambrosius Barth Verlag, Leipzig).
28. Lieblich, I., R. Yirmiya and J.C. Liebeskind, 1991, Intake of and preference for sweet solutions are attenuated in morphine-withdrawn rats, Behav. Neurosci. 105, 965.
29. 3H]mepyramine binding site represent the histamine H1 receptor? Re-examination of the histamine H1 receptor with quinine, J. Pharmacol. Exp. Ther. 268, 959.
30. Maier, W. and O. Benkert, 1994, Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies, Psychopharmacology 115, 495.
31. Markou, A. and G.F. Koob, 1991, Postcocaine anhedonia: An animal model of cocaine withdrawal, Neuropsychopharmacology 4, 17.
32. Matussek, N. and M. Hoche, 1989, Investigations with the specific mu-opiate receptor agonist fentanyl in depressive patients: growth hormone, prolactin, cortisol, noradrenaline and euphoric responses, Neuropsychobiology 21, 1.
33. Moller, H.J. and H.P. Volz, 1992, Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year, J. Affect. Disord. 26, 163.
34. Moreau, J.-L., R. Scherschlicht, F. Jenck and J.R. Martin, 1995, Chronic mild stress-induced anhedonia model of depression: REM sleep abnormalities and curative effects of electroshock treatment, Behav. Pharmacol. 6, 682.
35. Muscat, R., M. Papp and P. Willner, 1992, Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotoline, Psychopharmacology 109, 433.
36. Nath, C., A. Gulati, K.N. Dhawan and G.P. Gupta, 1988, Role of central histaminergic mechanism in behavioural depression, swimming despair, in mice, Life Sci. 42, 2413.
37. Nelson, J.C., 1987, The use of antipsychotic drugs in the treatment of depression, in: Treating Resistant Depression, ed. J. Zohar and R.H. Belmaker (PMA Corp., New York) p. 131.
38. Nickolson, V.J., J.H. Wieringa and A.M.L. Van Delft, 1982, Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin, Naunyn-Schmied. Arch. Pharmacol. 319, 48.
39. Noguchi, S., T. Inukai, T. Kuno and C. Tanaka, 1992a, The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking, Physiol Behav. 51, 1123.
40. Noguchi, S., Y. Fukuda and T. Inukai, 1992b, Possible contributory role of the central histaminergic system in the forced swimming model, Arneim.-Forsch./Drug Res. 42, 611.
41. Patch, I.C.L., B.M. Pitt and Y.M. Yeo, 1967, The direct comparison of antidepressants: imipramine and chlorprothixene, J. Psychiatr. Res. 5, 273.
42. Pickar, D., G.C. Davis, C. Schultz, I. Extein, R. Wagner, D. Naber, P.W. Gold, D.P. Van Kammen, F.K. Goodwin, R.J. Wyatt, C.H. Li and W.E. Bunney, 1981, Behavioral and biological effects of acute beta-endorphin injection in depressed and schizophrenic patients, Am. J. Psychiatr. 138, 160.
43. Poldinger, W., 1960, Ein Neurolepticum mit antidepressiver Wirkung "Taractan", Praxis 49, 468.
44. Randrup, A., I. Munkvad, R. Fog, J. Gerlach, L. Molander, B. Kjellberg and J. Scheel-Krüger, 1975, Mania, depression and brain dopamine, in: Current Developments in Psychopharmacology, Vol. 2, eds. W.B. Essman and L. Valzelli (Spectrum Press, New York) p. 206.
45. Ravn, J., A. Scharff and O. Aaskoven, 1980, 20 Jahre Erfahrungen mit Chlorprothixen, Pharmakopsychiatr. 13, 34.
46. Rickels, K., J.D. Amsterdam, C. Clary, G. Puzzoli and E. Schweizer, 1991, Buspirone in major depression: a controlled study, J. Clin. Psychiatr. 52, 34.
47. Robertson, M.M. and M.R. Trimble, 1981, Neuroleptics as antide-pressants, Neuropharmacology 20, 1335.
48. Satel, S.L. and J.C. Nelson, 1988, Stimulants in the treatment of depression: A critical overview, J. Clin. Psychiatr. 50, 241.
49. Scatton, B., G. Perrault, D.J. Sanger, H. Shoemaker, C. Carter, D. Fage, F. Gonon, K. Chergui, A. Cudennec and J. Benavides, 1994, Pharmacological profile of amisulpiride, an atypical neuroleptic which preferentially blocks presynaptic D2/D3 receptors, Neuropsychopharmacology 10, Suppl., Part 1, 242S.
50. Serra, G., A. Forgione, P.S. D'Aquila, M. Collu, W. Fratta and G.L. Gessa, 1990, Blockade of DA autoreceptors: Possible mechanism of antidepressant action of L-sulpiride, in: Dopamine and Mental Depression, ed. G.L. Gessa and G. Serra (Pergamon, Oxford) p. 185.
51. Siris, S., 1991, Diagnosis of secondary depression in schizophrenia. Implications for DSM-IV, Schizophr. Bull. 17, 75.
52. Sluzewska, A. and E. Nowakowska, 1994, The effects of carbamazepine, lithium and ketoconazole in chronic mild stress model of depression in rats, Behav Pharmacol 5, Suppl. 1, 86.
53. Thomson, R., 1982, Side effects and placebo amplification, Br. J. Psychiatr. 140, 64.
54. White, J.M. and G.R. Rumbold, 1988, Behavioral effects of histamine and its antagonists: a review, Psychopharmacology 95, 1.
55. Willner, P., 1995, Animal models of depression: validity and applications, in: Depression and Mania: from Neurobiology to Treatment, ed. G. Gessa, W. Fratta, L. Pani and G. Serra (Raven, New York) p. 19.
56. Willner, P., R. Muscat and M. Papp, 1992, Chronic mild stress-induced anhedonia: A realistic animal model of depression, Neurosci. Biobehav. Rev. 16, 525.
57. 3 receptor antagonist amisulpride, Psychopharmacology (in press).
58. Winer, B.J., 1971, Statistical Principles in Experimental Design (McGraw Hill, London).